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OBJECTIVES: To quantify medication adherence to
diuretic medication in heart failure (HF) patients and to
evaluate the relationship between adherence and health
care utilization. 
METHODS: Prospective, convenience sample; 
Adult patients with a current medical diagnosis of HF and
an active prescription for a diuretic from Wishard 
Memorial Hospital in Indianapolis, Indiana. Patients
were given a six-month supply of their diuretic in a bottle
capped with a microelectronic device (eDEM, Aprex Cor-
poration) to assess daily adherence (percentage of pre-
scribed doses taken) and scheduled adherence (percentage
of prescribed doses taken on time). Health care utiliza-
tion data were extracted from the Regenstrief Medical
Records System, which is Wishard’s clinical electronic
data repository. Data retrieved during the six-month
study period included numbers of hospitalizations and
emergency department (ED) visits classiﬁed as all reasons,
cardiac-related reasons, and heart failure-related reasons.
RESULTS: Patients (n = 42) were mostly single, middle-
aged patients with moderately severe HF. The mean daily
adherence and scheduled adherence were reported as
71.0% and 43.7%, respectively. All study patients were
hospitalized at least once during the study period and
most patients visited the ED. No relationship was found
between daily adherence and health care utilization.
However, signiﬁcant relationships were found between
scheduled adherence and both cardiac-related hospital
admissions (p = 0.0329) and cardiac-related ED visits 
(p = 0.0269). The risk of these clinical encounters
increased as scheduled adherence declined. 
CONCLUSION: These ﬁndings suggest that patients 
who are consistent with the administration of their loop
diuretic have fewer cardiac related hospitalizations and
ED visits. This result may be due to the known erratic
pharmacokinetic disposition of furosemide, the predom-
inate diuretic being used by patients in the study. Study
patients with low utilization may be taking their diuretic
at times that maximize the concentration-response rela-
tionship. This mechanism, and not the actual dose, may
contribute more to reduced utilization.
PCV37
EFFECT OF NON-ADHERENCE TO STATINS ON
ASSOCIATED COST EFFECTIVENESS
Heerey AM, Barry M
1National Centre for Pharmacoeconomics in Ireland, Dublin,
Ireland
OBJECTIVE: As lipid-lowering therapy is likely to be
long term and as many patients with hyperlipidemia 
are asymptomatic, adherence to HMG CoA Reductase
Inhibitors (statins) may be of relevance to the cost effec-
tiveness of these expensive agents. Therefore, rates of
statin usage in the Irish community setting were estab-
lished and effects on the incremental cost effectiveness
ratios (ICERs) of individual statin drugs in both primary
and secondary prevention of coronary heart disease
(CHD) calculated. 
METHODS: Non-adherence rates were established for
4,948 patients prescribed statins over an 18-month period
(Sept. 1999 to Feb. 2001) using a prescription-claims
database. A Markov model investigating the cost effec-
tiveness of statins, using Irish costs for medications and
acute myocardial infarction (AMI) treatment, Irish mor-
tality probabilities and outcomes for AMI and death from
the 4S trial for secondary prevention and the WOSCOPs
trial for primary prevention was adapted for these 
non-adherence rates. Changes in the discounted ICERs
per quality adjusted life year (QALY) were calculated.
RESULTS: Atorvastatin was the most cost-effective agent
in both primary and secondary prevention of CHD fol-
lowed by ﬂuvatstatin, simvastatin and pravastatin. ICERs
ranged from 1,172 to 3,900 Euro/QALY in secondary
prevention, increasing to 2,388 and 7,508 Euro/QALY
when non-adherence was factored. The effect in primary
prevention was even more apparent. Discounted
ICERs/QALY ranged from 17,668 Euro for atorvastatin
to 38,459 Euro for pravastatin. Effects of non-adherence
increased primary prevention ICERs to 24,663 and
57,494 Euro/QALY respectively. 
CONCLUSION: Non-adherence is rarely considered in
pharmacoeconomic evaluation. However, this study illus-
trates that non-compliance can have a signiﬁcant impact
on the cost effectiveness of all statins in the Irish setting.
This is likely to be the case for most expensive medica-
tions indicated over the long-term in all healthcare set-
tings. Therefore, the effects of non-compliance should be
considered before results from economic evaluation are
used to inﬂuence prescription choice.
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OBJECTIVES: Nonadherence is a major reason for mor-
bidity and mortality. The purpose of this study was to
determine medication adherence of patients post myocar-
dial infarction (MI). 
METHODS: Patients admitted to the University of
Michigan Medical Center with diagnosis of MI were iden-
tiﬁed consecutively and prospectively from July 1999 to
July 2000. Clinical data were obtained retrospectively
from medical records including medications at discharge.
Patients were interviewed by telephone six months after
discharge. Follow-up data included a self-reported list of
medications and a four-item adherence questionnaire.
RESULTS: Complete information was obtained from 
216 patients. The mean age was 63.4 (+12.6) years and
